BLOG

Aridis’ At-Home COVID-19 Therapy and Other Programs Primed for 2021 Inflections

Next year could be pivotal for Aridis. It anticipates inflection points for three immunotherapy programs and is making available for licensing its rapid mAb development technology platform, which identifies rare, potent, antibody-producing B cells for therapeutic development.